Trials / Active Not Recruiting
Active Not RecruitingNCT06883695
A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3045 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3045 Injection | SHR-3045 injection. |
| DRUG | SHR-3045 Placebo Injection | SHR-3045 placebo injection. |
Timeline
- Start date
- 2025-04-08
- Primary completion
- 2025-06-17
- Completion
- 2025-10-01
- First posted
- 2025-03-19
- Last updated
- 2025-08-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06883695. Inclusion in this directory is not an endorsement.